BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34428685)

  • 1. Acute exacerbation of asthma induced by combined therapy of programmed death-1 Blocker plus lenvatinib in a patient with advanced hepatocellular carcinoma.
    Wang H; Shi J; Wang X; Zhao H; Wang H
    Eur J Cancer; 2021 Oct; 156():122-124. PubMed ID: 34428685
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma.
    Fu S; Xu Y; Mao Y; He M; Chen Z; Huang S; Li D; Lv Y; Wu J
    Cancer Med; 2024 May; 13(9):e7105. PubMed ID: 38686567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.
    Torrens L; Montironi C; Puigvehí M; Mesropian A; Leslie J; Haber PK; Maeda M; Balaseviciute U; Willoughby CE; Abril-Fornaguera J; Piqué-Gili M; Torres-Martín M; Peix J; Geh D; Ramon-Gil E; Saberi B; Friedman SL; Mann DA; Sia D; Llovet JM
    Hepatology; 2021 Nov; 74(5):2652-2669. PubMed ID: 34157147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion.
    Zhang Y; Zhang H; Xu H; Wang Y; Feng L; Yi F
    World J Surg Oncol; 2024 May; 22(1):122. PubMed ID: 38711095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
    Yi C; Chen L; Lin Z; Liu L; Shao W; Zhang R; Lin J; Zhang J; Zhu W; Jia H; Qin L; Lu L; Chen J
    Hepatology; 2021 Nov; 74(5):2544-2560. PubMed ID: 34036623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma.
    Wang Y; Jiang M; Zhu J; Qu J; Qin K; Zhao D; Wang L; Dong L; Zhang X
    Biomed Pharmacother; 2020 Dec; 132():110797. PubMed ID: 33068935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review.
    Qiao ZY; Zhang ZJ; Lv ZC; Tong H; Xi ZF; Wu HX; Chen XS; Xia L; Feng H; Zhang JJ; Xia Q
    Front Immunol; 2021; 12():653437. PubMed ID: 34349755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody.
    Liu G; Zhou W; Li X; Guo L; He T; Zhao J; Gong L
    Front Immunol; 2021; 12():712351. PubMed ID: 34504494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and PD-1 inhibitors.
    Sun W; Yin X; Liu X; Wei J; Yu M; Li W; Ding X; Chen J
    Front Immunol; 2024; 15():1380477. PubMed ID: 38698848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A spontaneous rupture of lung metastasis from hepatocellular carcinoma after the introduction of lenvatinib.
    Higashino M; Sugiura R; Yamamoto Y; Naruse H; Sakamoto N
    J Gastrointestin Liver Dis; 2021 Mar; 30(1):169-170. PubMed ID: 33723551
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
    Kimura T; Kato Y; Ozawa Y; Kodama K; Ito J; Ichikawa K; Yamada K; Hori Y; Tabata K; Takase K; Matsui J; Funahashi Y; Nomoto K
    Cancer Sci; 2018 Dec; 109(12):3993-4002. PubMed ID: 30447042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
    Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
    J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeated Perforation of the Gallbladder in a Patient with Hepatocellular Carcinoma Receiving Lenvatinib.
    Honda S; Saito Y; Sawada K; Hasebe T; Nakajima S; Okumura T
    Intern Med; 2020 Mar; 59(5):657-662. PubMed ID: 31735795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenvatinib as a therapy for unresectable hepatocellular carcinoma.
    Spallanzani A; Orsi G; Andrikou K; Gelsomino F; Rimini M; Riggi L; Cascinu S
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1069-1076. PubMed ID: 30220234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Lenvatinib for Patients With Advanced Hepatocellular Carcinoma: A Retrospective, Real-world Study Conducted in Japan.
    Shimozato N; Namisaki T; Okano A; Ohana M; Kinoshita D; Kawasaki T; Aihara Y; Nakatani T; Kinoshita H; Ann T; Saito KO; Yoshida M; Yoshiji H
    Anticancer Res; 2022 Jan; 42(1):173-183. PubMed ID: 34969723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed cell death protein-1 inhibitor for the treatment of hepatocellular carcinoma: "A sharp sword".
    Li X; Liang P; Ye X
    J Cancer Res Ther; 2019; 15(2):267-268. PubMed ID: 30964095
    [No Abstract]   [Full Text] [Related]  

  • 17. Perforating dermatosis associated with multikinase inhibitors: report of two cases, including one associated with lenvatinib.
    Sato-Sano M; Cury-Martins J; Macarenco R; Domingues RB; Vasconcelos R; Sanches JA
    J Dtsch Dermatol Ges; 2018 Dec; 16(12):1486-1489. PubMed ID: 30466160
    [No Abstract]   [Full Text] [Related]  

  • 18. Pneumothorax during lenvatinib treatment for hepatocellular carcinoma with lung metastasis.
    Kawanishi Y; Kuwahara M; Utsunomiya M; Ishida N; Ishikawa Y; Hiroi M; Akimori T
    Clin J Gastroenterol; 2021 Feb; 14(1):288-292. PubMed ID: 33108567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib plus cisplatin for hepatocellular carcinoma.
    Brower V
    Lancet Oncol; 2016 Oct; 17(10):e424. PubMed ID: 27617663
    [No Abstract]   [Full Text] [Related]  

  • 20. Lenvatinib-Induced Tumor-Related Hemorrhages in Patients with Large Hepatocellular Carcinomas.
    Uchida-Kobayashi S; Kageyama K; Yamamoto A; Ikenaga H; Yoshida K; Kotani K; Kimura K; Odagiri N; Hagihara A; Fujii H; Enomoto M; Tamori A; Kubo S; Miki Y; Kawada N
    Oncology; 2021; 99(3):186-191. PubMed ID: 33032274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.